American Century Companies Inc. Purchases 11,291 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

American Century Companies Inc. boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,604,024 shares of the biopharmaceutical company’s stock after purchasing an additional 11,291 shares during the quarter. American Century Companies Inc. owned approximately 1.24% of Alnylam Pharmaceuticals worth $377,443,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Jennison Associates LLC acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $61,160,000. Strategic Financial Concepts LLC acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $41,529,000. Truist Financial Corp increased its holdings in shares of Alnylam Pharmaceuticals by 136.6% during the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company’s stock valued at $1,035,000 after acquiring an additional 2,539 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 3.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock valued at $67,464,000 after acquiring an additional 8,462 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Alnylam Pharmaceuticals by 13.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock valued at $4,687,000 after acquiring an additional 2,285 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the transaction, the executive vice president now directly owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. This represents a 4.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Pushkal Garg sold 1,548 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at approximately $3,017,271.63. This represents a 11.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ALNY shares. Sanford C. Bernstein cut their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a report on Friday. Royal Bank of Canada upped their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a research report on Friday. Bank of America upped their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a research report on Friday. Finally, JPMorgan Chase & Co. upped their target price on Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the company a “neutral” rating in a research report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $310.22.

Alnylam Pharmaceuticals Trading Up 11.8 %

Shares of NASDAQ:ALNY opened at $283.34 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The firm has a market capitalization of $36.68 billion, a price-to-earnings ratio of -130.57 and a beta of 0.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The business’s 50 day moving average price is $257.16 and its 200-day moving average price is $259.65.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.